F-18 FDG-PET/CT is a better predictor of progression-free and disease-specific survival than CE-CT when used to monitor treatment effects in women with metastatic breast cancer. Increasing the use of F-18 FDG-PET/CT could improve clinical decision-making and optimize treatment timing. However, more studies are needed to compare the two approaches.
Breast cancer is one of the most common types of cancer among women worldwide. Although early detection and treatment have shown significant improvement in the survival rates of breast cancer patients, metastatic breast cancer still contributes to a significant number of cancer-related deaths. Positron emission tomography (PET) and computed tomography (CT) are two imaging techniques … Read more